SILVER SPRING
Eylea HD dosing interval extended to 5 months
- Sponsor
- Regeneron Pharmaceuticals $REGN
- Drug
- Eylea HD · aflibercept
- Indication
- wet age-related macular degeneration and diabetic macular edema
FDA approved extended dosing intervals up to 5 months for Eylea HD (aflibercept) in wet age-related macular degeneration and diabetic macular edema.
What this means
Eylea HD is an eye injection that blocks abnormal blood vessel growth in wet macular degeneration and diabetic macular edema, helping prevent vision loss. The FDA now allows patients to receive the treatment every 5 months instead of more frequent doses after showing stable vision. This could mean fewer doctor visits for patients while maintaining the same vision protection, though individual response may vary.
Drug Watch — recent news on Eylea HD
- Regeneron stock trades steady as Eylea and Dupixent growth support earnings - ad-hoc-news.de
- Switching to Eylea HD extends injection intervals in DME patients | ASRS 2026 - Managed Healthcare Executive
- ASRS 2026: initiating aflibercept 8 mg or faricimab earlier improves durability and anatomic outcomes in real-world practice - Ophthalmology Times Europe
- Teva, Samsung Bioepis ink agreement for Eylea biosimilar in Canada - Drug Store News
- Bevacizumab surpasses Eylea as the most common retinal disease injection | ASRS 2026 - Managed Healthcare Executive
Sponsor Watch — recent news on Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals (REGN) Rebounds As Undervalued View Holds, Is The Upside Already Priced In?
- Merck Snags A First-Of-Its-Kind Approval, And Shares Jump
- Merck Stock Rises After U.S. Approval for Powerful Cholesterol-Cutting Pill
- Collect 9.8% On VRTX Stock Now, And Still Keep 15% Of Upside
- 1 Large-Cap Stock with Exciting Potential and 2 We Turn Down